cilostazol has been researched along with dipyridamole in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.45) | 18.7374 |
| 1990's | 1 (3.23) | 18.2507 |
| 2000's | 12 (38.71) | 29.6817 |
| 2010's | 14 (45.16) | 24.3611 |
| 2020's | 2 (6.45) | 2.80 |
| Authors | Studies |
|---|---|
| Bristol, JA; Cain, MH; Weishaar, RE | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Kawai, C; Murohara, Y; Takatsu, Y; Yui, Y | 1 |
| Sawada, M; Suzumura, A; Takayanagi, T; Tamaru, T; Yoshikawa, M | 1 |
| Ito, H; Kimura, Y; Ozeki, Y; Sudo, T | 1 |
| Inami, N; Iwasaka, T; Liu, Y; Nomura, S | 1 |
| Bricmont, P; Cone, J; Czerwiec, FS; Fong, M; Kambayashi, J; Le, SN; Liu, Y; Shoaf, SE; Sun, B; Tao, L; Yoshitake, M | 1 |
| Cone, J; Fong, M; Kambayashi, J; Li, H; Liu, Y; Yoshitake, M | 1 |
| Iwata, M; Nakamura, T; Uchiyama, S; Yamazaki, M | 1 |
| Liao, JK | 1 |
| Bhatt, DL; Meadows, TA | 1 |
| Iba, T | 1 |
| Kesteven, P; McCaslin, J; Smout, J; Stansby, G | 1 |
| Gomez, CR; Qureshi, AI | 1 |
| Diener, HC; Weber, R | 1 |
| Birnbaum, Y; Perez-Polo, JR; Ye, Y | 1 |
| Kamal, AK; Khan, M | 1 |
| Falcinelli, E; Gresele, P; Momi, S | 1 |
| Baglin, TP; Eikelboom, JW; Hirsh, J; Spencer, FA; Weitz, JI | 1 |
| Fisher, MJ; Liu, S; Paganini-Hill, A; Yang, F; Yu, C | 1 |
| Rondina, MT; Weyrich, AS | 1 |
| Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T | 1 |
| Azarbal, A; Clavijo, L; Gaglia, MA | 1 |
| Guo, ZN; Jin, H; Niu, PP; Xing, YQ; Yang, Y | 1 |
| Liu, X; Zhang, JJ | 1 |
| Longo, J; Minden, MD; Pandyra, AA; Penn, LZ; Schimmer, AD; Stachura, P | 1 |
| Liu, S; Shah, J; Yu, W | 1 |
15 review(s) available for cilostazol and dipyridamole
| Article | Year |
|---|---|
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Blood Platelets; Calmodulin; Cardiotonic Agents; Guinea Pigs; Humans; Hypersensitivity; In Vitro Techniques; Lung Diseases; Myocardium; Platelet Aggregation; Substrate Specificity | 1985 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyridamole; Disease Susceptibility; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Hemorrhage; Humans; Ischemic Attack, Transient; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recurrence; Stroke; Tetrazoles; Ticlopidine; Treatment Outcome; Vasodilator Agents | 2007 |
Clinical aspects of platelet inhibitors and thrombus formation.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Cardiovascular Diseases; Cilostazol; Clopidogrel; Dipyridamole; Drug Resistance; Humans; Pentanoic Acids; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2 Receptor Antagonists; Pyridines; Receptor, PAR-1; Stents; Tetrazoles; Thrombosis; Thromboxanes; Ticlopidine | 2007 |
[Pretreatment with cilostazol protects against the vascular endothelial damage after ischemia/reperfusion].
Topics: Animals; Aspirin; Cilostazol; Dipyridamole; Endothelial Cells; Ischemic Preconditioning; Mice; Phosphodiesterase Inhibitors; Reperfusion Injury; Tetrazoles | 2008 |
Oral antiplatelet agents and bleeding risk in relation to major cardiovascular surgery.
Topics: Aspirin; Cardiovascular Surgical Procedures; Cilostazol; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Risk; Tetrazoles; Ticlopidine | 2006 |
Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention.
Topics: Aspirin; Blood-Brain Barrier; Cilostazol; Clopidogrel; Dipyridamole; Drug Interactions; Drug Therapy, Combination; Humans; Lactones; Naphthalenes; Platelet Aggregation Inhibitors; Propionates; Pyridines; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke; Succinates; Tetrazoles; Thrombosis; Ticlopidine | 2010 |
Protecting against ischemia-reperfusion injury: antiplatelet drugs, statins, and their potential interactions.
Topics: Aspirin; Cilostazol; Dipyridamole; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Models, Cardiovascular; Myocardial Infarction; Myocardial Reperfusion Injury; Platelet Aggregation Inhibitors; Simvastatin; Tetrazoles | 2010 |
Anti-platelet therapy: phosphodiesterase inhibitors.
Topics: Blood Platelets; Cilostazol; Clinical Trials as Topic; Dipyridamole; Humans; Phosphodiesterase Inhibitors; Platelet Aggregation; Platelet Aggregation Inhibitors; Tetrazoles; Thrombosis | 2011 |
Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Aspirin; Cilostazol; Dipyridamole; Dose-Response Relationship, Drug; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Societies, Medical; Tetrazoles; Thienopyridines; Thrombosis; United States | 2012 |
Targeting phosphodiesterases in anti-platelet therapy.
Topics: Animals; Blood Platelets; Cilostazol; Dipyridamole; Humans; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; Tetrazoles | 2012 |
Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: guidelines abound, but where are the data?
Topics: Aspirin; Cilostazol; Dipyridamole; Endovascular Procedures; Extremities; Humans; Ischemia; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prostaglandins; Tetrazoles | 2015 |
Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
Topics: Aspirin; Cilostazol; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke; Tetrazoles; Ticlopidine | 2016 |
Aspirin plus dipyridamole has the highest surface under the cumulative ranking curves (SUCRA) values in terms of mortality, intracranial hemorrhage, and adverse event rate among 7 drug therapies in the treatment of cerebral infarction.
Topics: Aspirin; Cerebral Infarction; Cilostazol; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Hematologic Agents; Humans; Intracranial Hemorrhages; Tetrazoles; Ticlopidine; Warfarin | 2018 |
Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Humans; Ischemic Attack, Transient; Ischemic Stroke; Platelet Aggregation Inhibitors; Stroke; Ticagrelor | 2022 |
2 trial(s) available for cilostazol and dipyridamole
| Article | Year |
|---|---|
Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamole.
Topics: Aged; Arteriosclerosis Obliterans; Biomarkers; Case-Control Studies; Cell Adhesion Molecules; Cilostazol; Dipyridamole; Drug Synergism; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Particle Size; Platelet Activation; Tetrazoles | 2004 |
Cilostazol and dipyridamole synergistically inhibit human platelet aggregation.
Topics: Adenosine; Animals; Blood Platelets; CHO Cells; Cilostazol; Cricetinae; Cyclic AMP; Dipyridamole; Drug Synergism; Humans; Intracellular Membranes; Platelet Aggregation; Platelet Aggregation Inhibitors; Tetrazoles; Time Factors | 2004 |
14 other study(ies) available for cilostazol and dipyridamole
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
[The mode of action and clinical applications of phosphodiesterase inhibitors as anti-platelet drugs].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Cilostazol; Coronary Disease; Coronary Thrombosis; Cyclic AMP; Dipyridamole; Fibrinolytic Agents; Humans; Phosphodiesterase Inhibitors; Platelet Aggregation; Platelet Aggregation Inhibitors; Quinazolines; Tetrazoles | 1989 |
Effects of phosphodiesterase inhibitors on cytokine production by microglia.
Topics: 1-Methyl-3-isobutylxanthine; Amrinone; Animals; Anti-Ulcer Agents; Cilostazol; Colforsin; Dipyridamole; DNA Primers; Gene Expression Regulation, Enzymologic; Interleukin-1; Interleukin-6; Mice; Mice, Inbred C57BL; Microglia; Multiple Sclerosis; Papaverine; Pentoxifylline; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyrazines; Pyrrolidinones; Quinolines; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Rolipram; Tetrazoles; Theophylline; Tumor Necrosis Factor-alpha; Vinca Alkaloids; Xanthines | 1999 |
Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method.
Topics: Adenosine Diphosphate; Amino Acid Chloromethyl Ketones; Aspirin; Blood Coagulation; Blood Platelets; Cilostazol; Collagen; Dipyridamole; Filtration; Heparin; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Pressure; Tetrazoles; Time Factors; Tirofiban; Tyrosine | 2001 |
Antiplatelet and antithrombotic activity of cilostazol is potentiated by dipyridamole in rabbits and dissociated from bleeding time prolongation.
Topics: Animals; Bleeding Time; Carotid Artery Thrombosis; Cilostazol; Dipyridamole; Disease Models, Animal; Drug Synergism; In Vitro Techniques; Platelet Aggregation; Platelet Aggregation Inhibitors; Rabbits; Tetrazoles | 2005 |
Synergistic effect of cilostazol and dipyridamole mediated by adenosine on shear-induced platelet aggregation.
Topics: Adenosine; Adult; Cilostazol; Dipyridamole; Drug Synergism; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Shear Strength; Tetrazoles | 2007 |
Medical treatment of patients with intracranial atherosclerotic disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Embolism; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Arteriosclerosis; Intracranial Thrombosis; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Risk Factors; Tetrazoles; Ticlopidine | 2009 |
What is the best first agent to give to a patient with acute ischaemic stroke? Aspirin, heparin, clopidogrel, cilostazol or dipyridamole?
Topics: Aspirin; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Evidence-Based Medicine; Fibrinolytic Agents; Heparin; Humans; Platelet Aggregation Inhibitors; Stroke; Tetrazoles; Ticlopidine | 2010 |
Phosphodiesterase inhibitor modulation of brain microvascular endothelial cell barrier properties.
Topics: Actins; Brain; Capillary Permeability; Carbazoles; Cells, Cultured; Cilostazol; Claudin-5; Dipyridamole; Drug Interactions; Electric Impedance; Endothelial Cells; Histamine; Humans; Isoquinolines; Phosphodiesterase Inhibitors; Protein Kinase Inhibitors; Pyrroles; Rolipram; Sulfonamides; Tetrazoles | 2012 |
Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Dipyridamole; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Japan; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Secondary Prevention; Stroke; Succinates; Tablets, Enteric-Coated; Tetrazoles; Ticlopidine | 2014 |
Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death.
Topics: Cell Death; Cell Line, Tumor; Cilostazol; Cyclic AMP; Dipyridamole; Drug Synergism; Humans; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Models, Biological; Neoplasms; Phosphodiesterase Inhibitors; Sterols | 2020 |